New guidelines should offer relief for biotech patent applications rejected because they lack “utility”
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
35 U.S.C. § 101 (1988).
October 17, 1994, in San Diego, California.
The finalized version is found at 60 fed. Reg. 36,263 (July 14, 1995), reprinted with legal analysis in 50 Pat. Trademark & Copyright J. 295 (BNA1995). These Guidelines are not limited to biotechnology patent applications. They apply generally to all applications before the Office.
Manson, 383 U.S. at 534.
383 U.S. 519 (1966).
In re Manson, 33 F.2d 234,239,142 USPQ 35,39 (CCPA 1964) (Chief Judge Worley, dissenting).
In re Manson, 333 F.2d at 237, 142 USPQ at 37–38.
Id.
Id. at 856, 206 USPQ at 883.
Iizuka, 753 F.2d at 1051, 224 USPQ at 748.
Cross v. Iizuka, 753 F.2d 1040,224 USPQ 739 (Fed. Cir. 1985).
292 F.2d 948, 130 USPQ 215 (CCPA 1961).
628 F.2d 1322, 206 USPQ 885 (CCPA 1980).
Id. at 1327, 206 USPQ at 890.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Linck, N., Chambers, S. Utility in Biotech Patent Applications. Nat Biotechnol 13, 962–964 (1995). https://doi.org/10.1038/nbt0995-962
Issue date:
DOI: https://doi.org/10.1038/nbt0995-962
